scholarly article | Q13442814 |
P50 | author | Shabir A. Madhi | Q56065756 |
Asuncion Mejias | Q56487386 | ||
Harish Nair | Q61081121 | ||
Mike Sharland | Q61094965 | ||
Terho Heikkinen | Q38590173 | ||
Federico Martinón-Torres | Q41491268 | ||
Anne Greenough | Q43412070 | ||
P2093 | author name string | Louis Bont | |
Nikolaos G Papadopoulos | |||
Paolo Manzoni | |||
Brigitte Fauroux | |||
Fernando P Polack | |||
Octavio Ramilo | |||
Eugenio Baraldi | |||
Renato Stein | |||
Natalie I Mazur | |||
Respiratory Syncytial Virus Network (ReSViNET) | |||
P2860 | cites work | Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant | Q21091066 |
Bronchodilators for bronchiolitis | Q24193936 | ||
Nebulised hypertonic saline solution for acute bronchiolitis in infants | Q24200958 | ||
Glucocorticoids for acute viral bronchiolitis in infants and young children | Q24202303 | ||
Epinephrine for bronchiolitis | Q24236688 | ||
Grading quality of evidence and strength of recommendations | Q24562409 | ||
Duration of symptoms of respiratory tract infections in children: systematic review | Q24615215 | ||
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. | Q26782024 | ||
The role of early life viral bronchiolitis in the inception of asthma | Q26851823 | ||
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers | Q27667876 | ||
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody | Q27677570 | ||
Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes | Q28241147 | ||
Identification of nucleolin as a cellular receptor for human respiratory syncytial virus | Q28245563 | ||
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis | Q29619821 | ||
SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis | Q30423684 | ||
The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya | Q33596091 | ||
Pharmacologic advances in the treatment and prevention of respiratory syncytial virus | Q33776507 | ||
Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory | Q34059404 | ||
The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers | Q34079756 | ||
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
Direct medical costs of bronchiolitis hospitalizations in the United States. | Q50793631 | ||
Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. | Q51657773 | ||
High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study. | Q53602713 | ||
Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. | Q55053023 | ||
Failure of high-flow nasal cannula and delayed intubation: a new harmful sequence? | Q87170350 | ||
Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis | Q34445159 | ||
Diagnosis and management of bronchiolitis | Q34570865 | ||
Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy | Q34778067 | ||
The burden of respiratory syncytial virus infection in young children | Q34938343 | ||
Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma | Q34987105 | ||
Frequent Asymptomatic Respiratory Syncytial Virus Infections During an Epidemic in a Rural Kenyan Household Cohort | Q36250186 | ||
Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics | Q36276526 | ||
Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature | Q36607430 | ||
Determinants of asthma after severe respiratory syncytial virus bronchiolitis | Q36729353 | ||
Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age | Q37265589 | ||
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults | Q37335667 | ||
Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes | Q37570912 | ||
Strategic priorities for respiratory syncytial virus (RSV) vaccine development | Q37572640 | ||
Medicines used in respiratory diseases only seen in children | Q37589992 | ||
Diagnosis, management, and prognosis of preschool wheeze | Q38209053 | ||
Effect of oximetry on hospitalization in bronchiolitis: a randomized clinical trial | Q38425193 | ||
Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial | Q38429619 | ||
Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial | Q38429626 | ||
Oral GS-5806 activity in a respiratory syncytial virus challenge study. | Q42198937 | ||
Decreased lung function precedes severe respiratory syncytial virus infection and post-respiratory syncytial virus wheeze in term infants | Q42207500 | ||
Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. | Q42248000 | ||
Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011. | Q42251265 | ||
Respiratory syncytial virus and recurrent wheeze in healthy preterm infants | Q42263767 | ||
Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. | Q42282088 | ||
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine | Q43625547 | ||
Bronchiolitis management before and after the AAP guidelines | Q43766700 | ||
Hypertonic (3%) saline vs 0.93% saline nebulization for acute viral bronchiolitis: a randomized controlled trial | Q45158454 | ||
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). | Q45397417 | ||
Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial | Q45458064 | ||
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years | Q45747463 | ||
High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study. | Q46243372 | ||
Bronchiolitis-associated hospitalizations among US children, 1980-1996. | Q50653027 | ||
P433 | issue | 11 | |
P921 | main subject | maternal health | Q6786626 |
P304 | page(s) | 888-900 | |
P577 | publication date | 2015-09-24 | |
P1433 | published in | The Lancet. Respiratory medicine | Q27724908 |
P1476 | title | Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics | |
P478 | volume | 3 |
Q38849066 | A clustering approach to identify severe bronchiolitis profiles in children |
Q56794662 | A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats |
Q39027049 | Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection |
Q90690359 | Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits |
Q95283540 | Advanced "lab-on-a-chip" to detect viruses - Current challenges and future perspectives |
Q90024114 | An ethics framework and practical guidance for post-trial access to an RSV maternal vaccine |
Q91656519 | Anti-Respiratory Syncytial Virus Activity of Plantago asiatica and Clerodendrum trichotomum Extracts In Vitro and In Vivo |
Q39028034 | Best practices in the treatment of early cystic fibrosis lung disease |
Q28551925 | Biochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA Polymerase |
Q47562812 | Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts |
Q98735544 | Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV |
Q53693691 | Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. |
Q96436602 | Chemokine (C-X-C motif) Ligand 4 is a Restrictor of Respiratory Syncytial Virus Infection and an Indicator of Clinical Severity |
Q39294045 | Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children |
Q42362274 | Community-acquired pneumonia in children - a changing spectrum of disease |
Q49728845 | Comparison of the prevalence of respiratory viruses in patients with acute respiratory infections at different hospital settings in North China, 2012-2015. |
Q45324366 | Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants |
Q50793129 | Deciphering clinical phenotypes in acute viral lower respiratory tract infection: Bronchiolitis is not an island. |
Q28067464 | Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease |
Q40060466 | Determining the outcomes of interventions to prevent respiratory syncytial virus disease in children: what to measure? |
Q38969434 | Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection |
Q59357659 | Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability |
Q47392075 | Discharge Criteria for Bronchiolitis: An Unmet Need |
Q28076551 | Early-life respiratory infections and asthma development: role in disease pathogenesis and potential targets for disease prevention |
Q36169484 | Epidemiology and Clinical Presentations of Respiratory Syncytial Virus Subgroups A and B Detected with Multiplex Real-Time PCR |
Q54610317 | Establishment of childhood pneumonia cause in the era of pneumococcal conjugate vaccines. |
Q36275637 | Etiology of severe pneumonia in Ecuadorian children |
Q59353230 | Exchange Proteins Directly Activated by cAMP and Their Roles in Respiratory Syncytial Virus Infection |
Q37049972 | Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts |
Q30148692 | Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance |
Q40040542 | Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series |
Q38687853 | Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study |
Q38752668 | Heme Oxygenase-1 Modulates Human Respiratory Syncytial Virus Replication and Lung Pathogenesis during Infection |
Q38657710 | Identification of two novel functional tRNA-derived fragments induced in response to respiratory syncytial virus infection |
Q40043100 | Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines |
Q98775560 | Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions |
Q59355642 | Increased severity of respiratory syncytial virus airway infection due to passive smoke exposure |
Q29248088 | Influenza and respiratory syncytial virus in infants study (IRIS) of hospitalized and non-ill infants aged <1 year in four countries: study design and methods |
Q60954877 | Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia |
Q96680272 | Interleukin-22 Inhibits Respiratory Syncytial Virus Production by Blocking Virus-Mediated Subversion of Cellular Autophagy |
Q38744226 | Latest options for treatment of bronchiolitis in infants |
Q37719544 | Management of acute respiratory diseases in the pediatric population: the role of oral corticosteroids |
Q46622417 | Meeting Report: Harmonization of RSV therapeutics – from design to performance |
Q59350800 | Metabolomic profiling of infants with recurrent wheezing after bronchiolitis |
Q47548281 | Molecular epidemiology of human respiratory syncytial virus among children in Japan during three seasons and hospitalization risk of genotype ON1. |
Q53601809 | Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries. |
Q100407560 | Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial |
Q40403859 | New Insights into Structural Disorder in Human Respiratory Syncytial Virus Phosphoprotein and Implications for Binding of Protein Partners. |
Q88290056 | Otitis media |
Q39318498 | Passive and active immunization against respiratory syncytial virus for the young and old. |
Q90580234 | Pharmacokinetics, Safety and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized with RSV Infection: A Randomized Phase 1b Study |
Q38941657 | Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects |
Q92640553 | Prescribing for bronchiolitis: think globally, choose wisely |
Q90953271 | Prevalence of infant bronchiolitis-coded healthcare encounters attributable to RSV |
Q39967767 | Prevalence, codetection and seasonal distribution of upper airway viruses and bacteria in children with acute respiratory illnesses with cough as a symptom. |
Q40110283 | Promising approaches for the treatment and prevention of viral respiratory illnesses |
Q47554686 | Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. |
Q40332252 | Respiratory Syncytial Virus (RSV) Infects CD4+ T Cells: Frequency of Circulating CD4+ RSV+ T Cells as a Marker of Disease Severity in Young Children |
Q64894378 | Respiratory Syncytial Virus Seasonality, Beijing, China, 2007-2015. |
Q57461131 | Respiratory Syncytial Virus-induced Acute Disease Severity and Long-Term Wheezing. Uncovering the Unexpected |
Q30240274 | Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment |
Q50143928 | Respiratory syncytial virus activates epidermal growth factor receptor to suppress interferon regulatory factor 1-dependent interferon-lambda and antiviral defense in airway epithelium. |
Q37577700 | Respiratory syncytial virus infection: an innate perspective |
Q49817370 | Respiratory syncytial virus is an "opportunistic" killer |
Q40933386 | Respiratory syncytial virus trials and beyond |
Q38803541 | Respiratory syncytial virus vaccines: an update on those in the immediate pipeline. |
Q39198689 | Respiratory syncytial virus-Host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life. |
Q38888943 | Review of the clinical significance of respiratory virus infections in newborn infants |
Q41922224 | Role of viral infections in the development and exacerbation of asthma in children |
Q54299508 | Seasonal immunisation against respiratory syncytial virus disease. |
Q40419642 | Severity of Respiratory Syncytial Virus Lower Respiratory Tract Infection With Viral Coinfection in HIV-Uninfected Children |
Q58778749 | Surveillance for respiratory syncytial virus and parainfluenza virus among patients hospitalized with pneumonia in Sarawak, Malaysia |
Q40096615 | The Susceptibilities of Respiratory Syncytial Virus to Nucleolin Receptor Blocking and Antibody Neutralization are Dependent upon the Method of Virus Purification |
Q55473370 | The impact of modifiable risk factor reduction on childhood asthma development. |
Q57026345 | The impact of respiratory viruses on lung health after preterm birth |
Q59358526 | The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates |
Q38789297 | The role of the NxTAG® respiratory pathogen panel assay and other multiplex platforms in clinical practice |
Q38650711 | Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor |
Q40051899 | Tissue compartmentalization of T cell responses during early life |
Q47549703 | Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses |
Q57019179 | Viral Sepsis in Children |
Q30248348 | Viral bronchiolitis. |
Q64375170 | Viral pathogens associated with acute lower respiratory tract infections in children younger than 5 years of age in Bulgaria |
Q39199043 | Viruses in cystic fibrosis patients' airways |
Q45324472 | Whole Exome Sequencing reveals new candidate genes in host genomic susceptibility to Respiratory Syncytial Virus Disease. |
Search more.